Alnylam Pharmaceuticals faces significant pressure as its stock continues to decline amidst market concerns.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) experienced a downturn today, with shares falling by 1.79%, closing at CA$241.11. This decline follows a broader trend of skepticism surrounding the company's growth prospects and market positioning.
Investor takeaway: Investors should be cautious as Alnylam's recent performance raises concerns about its ability to navigate pricing pressures and maintain growth in a competitive landscape.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$32.03B
P/E
41.5x
52W high
$495.55
52W low
$197.81
1W change
-7.22%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 55.1% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+55.1% Upside
Current Price
C$239.36
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.4%
Annualized
90-Day Vol
80.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$205.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$231.32 | C$196.42 – C$272.43 |
| 60 trading days | C$217.96 | C$172.94 – C$274.68 |
| 90 trading days | C$205.36 | C$154.70 – C$272.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.79% decline in share price
Alnylam's stock has dropped significantly, reflecting investor concerns about its pricing strategies and competitive positioning in the RNAi therapeutics market.
Bull case
Despite today's decline, analysts are optimistic about Alnylam's long-term potential. They point to strong revenue growth and a promising pipeline of RNAi therapies that could boost future earnings.
Bear case
The current sell-off highlights ongoing worries about pricing pressures on Alnylam's flagship products and the company's ability to sustain revenue growth amid rising competition.
Market Reaction and Performance
Advertisement
Alnylam's stock performance today reflects a broader market sentiment that has turned cautious. The 1.79% drop in share price comes as investors digest recent news regarding potential pricing pressures on its RNA interference therapies. With a market cap of CA$32.85 billion, Alnylam is navigating a challenging landscape where competition is intensifying, particularly in the treatment of rare diseases.
Analyst Perspectives
Despite the current downturn, many analysts maintain a bullish outlook on Alnylam. Of 29 analysts surveyed, 22 rated the stock as a 'buy' or 'strong buy'. They cite the company's strong revenue growth trajectory and the potential for its pipeline of RNAi therapies to deliver significant returns in the long run. However, ongoing concerns about pricing strategies and market competition could weigh heavily on investor sentiment.
Future Outlook
Looking ahead, Alnylam's ability to recover from this decline hinges on its execution of key clinical trials and the successful launch of new therapies. The company is expected to face continued scrutiny regarding its pricing strategies, especially as competitors emerge in the RNAi space. Investors will need to closely monitor these developments to gauge the company's long-term viability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
